Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for L&C Bio Co., Ltd. (290650:KRX), powered by AI.
L&C Bio Co., Ltd. is currently trading at ₩76,200. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for L&C Bio Co., Ltd. on Alpha Lenz.
L&C Bio Co., Ltd.'s P/E ratio is -14.9.
“L&C Bio Co., Ltd. trades at a P/E of -14.9 (undervalued) with modest ROE of -57.3%. 3Y revenue CAGR of 17.6% highlights clear growth momentum.”
Ask for details →L&C Bio Co., Ltd. is a prominent player in the biotechnology and life sciences sector, specializing in the research, development, and commercialization of regenerative medicine solutions. The company's primary focus lies in the development of innovative products aimed at promoting skin rejuvenation and wound healing. A key aspect of L&C Bio's product lineup includes advanced biomaterials derived from collagen, which play a crucial role in medical and cosmetic applications. L&C Bio Co., Ltd. significantly impacts the healthcare industry by providing state-of-the-art solutions that cater to both medical professionals and end consumers seeking effective treatments. With a strong emphasis on R&D, the company collaborates with various research institutions and invests heavily in technological advancements to maintain a competitive edge. L&C Bio's importance in the market is underscored by its commitment to enhancing patient outcomes and improving the quality of life through cutting-edge biotechnological innovations.
“L&C Bio Co., Ltd. trades at a P/E of -14.9 (undervalued) with modest ROE of -57.3%. 3Y revenue CAGR of 17.6% highlights clear growth momentum.”
Ask for details →L&C Bio Co., Ltd. (ticker: 290650) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 130 employees. Market cap is $2.1T.
The current price is ₩76,200 with a P/E ratio of -14.87x and P/B of 10.37x.
ROE is -57.27% and operating margin is 5.17%. Annual revenue is $85.5B.